ArticleFrontiers in oncology2020

SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer.

Arthur-Quan Tran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.